114 related articles for article (PubMed ID: 24139584)
1. Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depression.
Gao Z; Hurst WJ; Czechtizky W; Hall D; Moindrot N; Nagorny R; Pichat P; Stefany D; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Dec; 23(23):6269-73. PubMed ID: 24139584
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.
Gao Z; Hurst WJ; Guillot E; Nagorny R; Pruniaux MP; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Jul; 23(14):4044-7. PubMed ID: 23769643
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategy.
Gao Z; Hurst WJ; Hall D; Hartung R; Reynolds W; Kang J; Nagorny R; Hendrix JA; George PG
Bioorg Med Chem; 2015 Feb; 23(3):429-38. PubMed ID: 25577710
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
Gao Z; Hurst WJ; Czechtizky W; Francon D; Griebel G; Nagorny R; Pichat P; Schwink L; Stengelin S; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Nov; 23(22):6141-5. PubMed ID: 24076172
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
[TBL] [Abstract][Full Text] [Related]
6. Phenyl-oxazoles, a new family of inverse agonists at the H(3) histamine receptor.
Denonne F; Atienzar F; Célanire S; Christophe B; Delannois F; Delaunoy C; Delporte ML; Durieu V; Gillard M; Lallemand B; Lamberty Y; Lorent G; Vanbellinghen A; Van Houtvin N; Verbois V; Provins L
ChemMedChem; 2010 Feb; 5(2):206-12. PubMed ID: 20043314
[No Abstract] [Full Text] [Related]
7. 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.
Hudkins RL; Becknell NC; Lyons JA; Aimone LD; Olsen M; Haltiwanger RC; Mathiasen JR; Raddatz R; Gruner JA
Eur J Med Chem; 2015 May; 95():349-56. PubMed ID: 25827402
[TBL] [Abstract][Full Text] [Related]
8. Cinnamic amides of (S)-2-(aminomethyl)pyrrolidines are potent H3 antagonists.
Peschke B; Bak S; Hohlweg R; Pettersson I; Refsgaard HH; Viuff D; Rimvall K
Bioorg Med Chem; 2004 May; 12(10):2603-16. PubMed ID: 15110842
[TBL] [Abstract][Full Text] [Related]
9. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
Zhang M; Ballard ME; Pan L; Roberts S; Faghih R; Cowart M; Esbenshade TA; Fox GB; Decker MW; Hancock AA; Rueter LE
Brain Res; 2005 May; 1045(1-2):142-9. PubMed ID: 15910772
[TBL] [Abstract][Full Text] [Related]
10. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
Bioorg Med Chem Lett; 2013 Jun; 23(11):3421-6. PubMed ID: 23591112
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
Fox GB; Esbenshade TA; Pan JB; Radek RJ; Krueger KM; Yao BB; Browman KE; Buckley MJ; Ballard ME; Komater VA; Miner H; Zhang M; Faghih R; Rueter LE; Bitner RS; Drescher KU; Wetter J; Marsh K; Lemaire M; Porsolt RD; Bennani YL; Sullivan JP; Cowart MD; Decker MW; Hancock AA
J Pharmacol Exp Ther; 2005 Apr; 313(1):176-90. PubMed ID: 15608077
[TBL] [Abstract][Full Text] [Related]
12. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
[TBL] [Abstract][Full Text] [Related]
13. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
[No Abstract] [Full Text] [Related]
14. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
15. From ergolines to indoles: improved inhibitors of the human H3 receptor for the treatment of narcolepsy.
Auberson YP; Troxler T; Zhang X; Yang CR; Feuerbach D; Liu YC; Lagu B; Perrone M; Lei L; Shen X; Zhang D; Wang C; Wang TL; Briner K; Bock MG
ChemMedChem; 2015 Feb; 10(2):266-75. PubMed ID: 25394333
[TBL] [Abstract][Full Text] [Related]
16. Novel substituted pyrrolidines are high affinity histamine H3 receptor antagonists.
Stocking EM; Aluisio L; Atack JR; Bonaventure P; Carruthers NI; Dugovic C; Everson A; Fraser I; Jiang X; Leung P; Lord B; Ly KS; Morton KL; Nepomuceno D; Shah CR; Shelton J; Soyode-Johnson A; Letavic MA
Bioorg Med Chem Lett; 2010 May; 20(9):2755-60. PubMed ID: 20382018
[TBL] [Abstract][Full Text] [Related]
17. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
Hancock AA; Diehl MS; Faghih R; Bush EN; Krueger KM; Krishna G; Miller TR; Wilcox DM; Nguyen P; Pratt JK; Cowart MD; Esbenshade TA; Jacobson PB
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):144-52. PubMed ID: 15447739
[TBL] [Abstract][Full Text] [Related]
18. Anticonvulsant properties of histamine H3 receptor ligands belonging to N-substituted carbamates of imidazopropanol.
Sadek B; Shehab S; Więcek M; Subramanian D; Shafiullah M; Kieć-Kononowicz K; Adem A
Bioorg Med Chem Lett; 2013 Sep; 23(17):4886-91. PubMed ID: 23891186
[TBL] [Abstract][Full Text] [Related]
19. Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.
Covel JA; Santora VJ; Smith JM; Hayashi R; Gallardo C; Weinhouse MI; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Pulley MD; Smith BM; Ren A; Suarez M; Frazer J; Edwards J; Hauser EK; Lorea J; Semple G; Grottick AJ
J Med Chem; 2009 Sep; 52(18):5603-11. PubMed ID: 19722526
[TBL] [Abstract][Full Text] [Related]
20. N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands.
Więcek M; Kottke T; Ligneau X; Schunack W; Seifert R; Stark H; Handzlik J; Kieć-Kononowicz K
Bioorg Med Chem; 2011 May; 19(9):2850-8. PubMed ID: 21498080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
